• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓基质细胞衍生的外泌体在多发性骨髓瘤细胞耐药中的通讯作用。

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

机构信息

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium; Research Center for Immunology, Xinxiang Medical University, Xinxiang, Henan, People's Republic of China;

Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium; and.

出版信息

Blood. 2014 Jul 24;124(4):555-66. doi: 10.1182/blood-2014-03-562439. Epub 2014 Jun 13.

DOI:10.1182/blood-2014-03-562439
PMID:24928860
Abstract

The interplay between bone marrow stromal cells (BMSCs) and multiple myeloma (MM) cells performs a crucial role in MM pathogenesis by secreting growth factors, cytokines, and extracellular vesicles. Exosomes are membranous vesicles 40 to 100 nm in diameter constitutively released by almost all cell types, and they mediate local cell-to-cell communication by transferring mRNAs, miRNAs, and proteins. Although BMSC-induced growth and drug resistance of MM cells has been studied, the role of BMSC-derived exosomes in this action remains unclear. Here we investigate the effect of BMSC-derived exosomes on the viability, proliferation, survival, migration, and drug resistance of MM cells, using the murine 5T33MM model and human MM samples. BMSCs and MM cells could mutually exchange exosomes carrying certain cytokines. Both naive and 5T33 BMSC-derived exosomes increased MM cell growth and induced drug resistance to bortezomib. BMSC-derived exosomes also influenced the activation of several survival relevant pathways, including c-Jun N-terminal kinase, p38, p53, and Akt. Exosomes obtained from normal donor and MM patient BMSCs also induced survival and drug resistance of human MM cells. Taken together, our results demonstrate the involvement of exosome-mediated communication in BMSC-induced proliferation, migration, survival, and drug resistance of MM cells.

摘要

骨髓基质细胞(BMSCs)与多发性骨髓瘤(MM)细胞之间的相互作用通过分泌生长因子、细胞因子和细胞外囊泡在 MM 发病机制中发挥关键作用。外泌体是几乎所有细胞类型都持续释放的直径为 40 至 100nm 的膜性囊泡,通过转移 mRNAs、miRNAs 和蛋白质来介导局部细胞间通讯。尽管已经研究了 BMSC 诱导的 MM 细胞生长和耐药性,但 BMSC 衍生的外泌体在这种作用中的作用尚不清楚。在这里,我们使用鼠 5T33MM 模型和人 MM 样本研究了 BMSC 衍生的外泌体对 MM 细胞活力、增殖、存活、迁移和耐药性的影响。BMSCs 和 MM 细胞可以相互交换携带某些细胞因子的外泌体。幼稚和 5T33 BMSC 衍生的外泌体均增加 MM 细胞生长并诱导硼替佐米耐药。BMSC 衍生的外泌体还影响几种存活相关途径的激活,包括 c-Jun N 末端激酶、p38、p53 和 Akt。来自正常供体和 MM 患者 BMSCs 的外泌体也诱导人 MM 细胞的存活和耐药性。总之,我们的结果表明,外泌体介导的通讯参与了 BMSC 诱导的 MM 细胞增殖、迁移、存活和耐药性。

相似文献

1
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.骨髓基质细胞衍生的外泌体在多发性骨髓瘤细胞耐药中的通讯作用。
Blood. 2014 Jul 24;124(4):555-66. doi: 10.1182/blood-2014-03-562439. Epub 2014 Jun 13.
2
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.在SN38介导的对多发性骨髓瘤的细胞毒性作用中,拓扑异构酶I的蛋白酶体降解之前会发生c-Jun氨基末端激酶激活、Fas上调和聚(ADP-核糖)聚合酶裂解。
Cancer Res. 2004 Dec 1;64(23):8746-53. doi: 10.1158/0008-5472.CAN-04-2894.
3
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.靶向线粒体以克服多发性骨髓瘤(MM)细胞中的传统耐药性及硼替佐米/蛋白酶体抑制剂PS-341耐药性。
Blood. 2004 Oct 15;104(8):2458-66. doi: 10.1182/blood-2004-02-0547. Epub 2004 Jun 24.
4
Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.c-Met 敲低通过抑制 Akt/mTOR 活性增强人多发性骨髓瘤 U266 细胞对硼替佐米的敏感性。
APMIS. 2012 Mar;120(3):195-203. doi: 10.1111/j.1600-0463.2011.02836.x. Epub 2011 Nov 11.
5
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.硼替佐米耐药的多发性骨髓瘤细胞核因子-κB活性
Mol Cancer Res. 2008 Aug;6(8):1356-64. doi: 10.1158/1541-7786.MCR-08-0108.
6
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.骨髓基质衍生的可溶性因子和直接细胞接触通过不同机制促成骨髓瘤细胞的获得性耐药。
Leukemia. 2003 Jun;17(6):1175-82. doi: 10.1038/sj.leu.2402924.
7
Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.Toll样受体(TLR)-1/2激活多发性骨髓瘤细胞可调节其与骨髓基质细胞的黏附,并增强硼替佐米诱导的细胞凋亡。
PLoS One. 2014 May 2;9(5):e96608. doi: 10.1371/journal.pone.0096608. eCollection 2014.
8
Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.半乳糖凝集素-9 通过 JNK 和 p38 MAP 激酶通路发挥抗骨髓瘤活性。
Leukemia. 2010 Apr;24(4):843-50. doi: 10.1038/leu.2010.25. Epub 2010 Mar 4.
9
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.蛋白酶体抑制剂PS-341可抑制人多发性骨髓瘤细胞的生长、诱导其凋亡并克服耐药性。
Cancer Res. 2001 Apr 1;61(7):3071-6.
10
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.BIRB 796通过抑制多发性骨髓瘤细胞系中的p38丝裂原活化蛋白激酶/Hsp27途径增强硼替佐米、热休克蛋白(Hsp)90抑制剂和地塞米松引发的细胞毒性,并抑制旁分泌肿瘤生长。
Br J Haematol. 2007 Feb;136(3):414-23. doi: 10.1111/j.1365-2141.2006.06443.x. Epub 2006 Dec 14.

引用本文的文献

1
Potential role of miR-29b from mesenchymal stromal cell-derived extracellular vesicles in leukemic cell progression.间充质基质细胞衍生的细胞外囊泡中的miR-29b在白血病细胞进展中的潜在作用。
PLoS One. 2025 Sep 10;20(9):e0328922. doi: 10.1371/journal.pone.0328922. eCollection 2025.
2
Syntenin inhibition impairs stroma-tumor communication in multiple myeloma and improves bortezomib treatment efficiency.syntenin抑制作用会损害多发性骨髓瘤中的基质-肿瘤通讯,并提高硼替佐米的治疗效果。
Hemasphere. 2025 Aug 18;9(8):e70197. doi: 10.1002/hem3.70197. eCollection 2025 Aug.
3
Engineered EVs-Mediated miR-222 Targeting PTEN/FN1 Axis Reverses Anthracycline Resistance in HER2-Negative Breast Cancer.
工程化细胞外囊泡介导的miR-222靶向PTEN/FN1轴逆转HER2阴性乳腺癌中的蒽环类耐药性
Cancer Sci. 2025 Sep;116(9):2547-2567. doi: 10.1111/cas.70118. Epub 2025 Jun 12.
4
Exosome-Mediated Chemoresistance in Cancers: Mechanisms, Therapeutic Implications, and Future Directions.外泌体介导的癌症化疗耐药性:机制、治疗意义及未来方向
Biomolecules. 2025 May 8;15(5):685. doi: 10.3390/biom15050685.
5
Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.间充质干细胞来源外泌体在抗肿瘤药物靶向递送中的研究进展
Cancer Cell Int. 2025 Apr 29;25(1):169. doi: 10.1186/s12935-025-03795-x.
6
Exploring the Interaction of Tumor-Derived Exosomes and Mesenchymal Stem Cells in Tumor Biology.探索肿瘤来源外泌体与间充质干细胞在肿瘤生物学中的相互作用
Int J Mol Sci. 2025 Mar 27;26(7):3095. doi: 10.3390/ijms26073095.
7
Advances in Tracing Techniques: Mapping the Trajectory of Mesenchymal Stem-Cell-Derived Extracellular Vesicles.追踪技术的进展:绘制间充质干细胞衍生细胞外囊泡的轨迹
Chem Biomed Imaging. 2025 Feb 2;3(3):137-168. doi: 10.1021/cbmi.4c00085. eCollection 2025 Mar 24.
8
From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma.从生物学至临床实践:多发性骨髓瘤中的骨髓微环境
J Clin Med. 2025 Jan 8;14(2):327. doi: 10.3390/jcm14020327.
9
In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?血液系统恶性肿瘤的体外3D模型:当前趋势与未来之路?
Cells. 2025 Jan 2;14(1):38. doi: 10.3390/cells14010038.
10
Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.利用外泌体的力量用于血液系统恶性肿瘤的诊断、预后评估和治疗。
Stem Cell Res Ther. 2025 Jan 7;16(1):6. doi: 10.1186/s13287-024-04125-0.